Roche/Genentech
Executive Summary
Merger complete on schedule, firms announced Sept. 7. Roche received go-ahead to acquire 60% equity in Genentech in a $2.1 bil. transaction when the two firms entered a consent decree with the Federal Trade Commission Aug. 31 ("The Pink Sheet" Sept. 3, T&G-1).